This is a working overview of ACTH(4-10), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Separates target peptide from truncated and oxidised forms |
| Identity confirmation | LC-MS or ESI-MS | Compares observed and calculated molecular ion |
| Primary degradation route | Methionine oxidation | Forms the sulfoxide; monitored as an early-eluting peak |
| Short-term storage | 2 to 8 degrees Celsius | Applies to working vials and reconstituted portions |
| Common synonyms | ACTH(4–10) analogue, MEHFPGP | Descriptive names used in laboratory catalogues |
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
=== Time and temperature indicators === Temperature indicators show that a specified temperature has been reached or exceeded. Time–temperature indicators respond to cumulative exposure over time and can provide an indication of the thermal history of a product. Indicators may use chemical, enzymatic, microbial, mechanical, electronic, or colour-changing mechanisms. They are used with foods, vaccines, pharmaceuticals, biological materials, and other temperature-sensitive goods. Electronic temperature data loggers can record the time, duration, and extent of temperature deviations. Thermochromic inks provide reversible or irreversible colour changes when particular temperatures are reached.
=== Personal life and death === Dyson married his first wife, the Swiss mathematician Verena Huber, on 11 August 1950. They had two children, Esther and George, before divorcing in 1958. In November 1958 he married Imme Jung, with whom he had four daughters. Dyson died on 28 February 2020 at Penn Medicine Princeton Medical Center in Plainsboro Township, New Jersey, from complications following a fall. He was 96.
Insulin potentiation therapy (IPT) is an unproven alternative cancer treatment using insulin as an adjunct to low-dose chemotherapy. It was promoted by a paper in the controversial and non-peer reviewed journal Medical Hypotheses. It is not an evidence-based cancer treatment, and the costs of IPT are not covered by health insurance. According to Quackwatch, "Insulin Potentiation Therapy (IPT) is one of several unproven, dangerous treatments that is promoted by a small group of practitioners without trustworthy evidence that it works."
== BDNF-AS == The genomic locus encoding BDNF is structurally complex and also encodes BDNF-antisense (BDNF-AS; also known as BDNFOS or ANTI-BDNF). BDNF-AS is a long non-coding RNA (lncRNA) transcribed from the opposite strand of the BDNF gene. This lncRNA was identified in 2005 through searches in expressed sequence tag (EST) databases and subsequent RT-PCR experiments. The gene encoding BDNF-AS is located on chromosome 11p14.1. BDNF mRNA and BDNF-AS share a common overlapping region and form double-stranded RNA (dsRNA) duplexes. BDNF-AS regulates BDNF expression and can suppress BDNF mRNA. In the human neocortex, regions with increased activity and BDNF expression exhibit reduced BDNF-AS expression. Elevated BDNF-AS levels are associated with reduced BDNF expression and have been shown to promote neurotoxicity, increase apoptosis, and decrease cell viability. Conversely, inhibiting BDNF-AS upregulates BDNF mRNA, activates BDNF-mediated signaling pathways, increases BDNF protein levels, suppresses neuronal apoptosis, and promotes neuronal outgrowth and differentiation. The BDNF-AS gene consists of 10 exons and a functional promoter upstream of exon 1. The BDNF-AS gene generates numerous distinct non-coding RNAs through alternative splicing. This diversity of spliced isoforms is a common feature of eukaryotic organisms, particularly in the nervous system. Notably, BDNF-AS is absent in rodents, although highly homologous sequences are present in the genomes of chimpanzees and rhesus monkeys, suggesting a primate/hominid evolutionary origin of BDNF-AS.
Sources: en.wikipedia.org
=== Degrees === Petechiae – small pinpoint hematomas less than 3 mm in diameter; Purpura (purple) – a bruise about 3–10 mm in diameter, generally round in shape; Ecchymosis – subcutaneous extravasation of blood in a thin layer under the skin, i.e. bruising, over 1 cm in diameter.
=== Other drugs === Alosetron — used in the management of severe chronic diarrhea-predominant irritable bowel syndrome (IBS-D) in females not responsive to conventional therapy; its use is restricted due to serious gastrointestinal adverse reactions, such ischemic colitis and complications of constipation. Cisapride — used for severe gastroesophageal reflux disease (GERD); carries risk of heart arrhythmias. Clomethiazole — a sedative/hypnotic agent used in the treatment of alcohol withdrawal when benzodiazepines are not effective; its use is limited due to its high toxicity and potential for addiction. Clozapine — used in treatment-resistant schizophrenia not responsive to at least two different antipsychotics; its use is limited due to the risk of severe side effects including agranulocytosis, seizures and myocarditis. Felbamate — an anticonvulsant used in refractory epilepsy; associated with an increased risk of aplastic anemia and liver failure. Isotretinoin — used when all topical treatments or antibiotics against acne have failed, it permanently dries out the sebum production of the skin and is often a permanent solution against acne; can cause severe side effects including severe nosebleeds, birth defects when taken while pregnant, depression, hair loss and can permanently dry out the skin all over the body. Levosimendan — used in acutely decompensated severe chronic heart failure in situations where conventional therapy is not sufficient; not yet approved in the US.
=== Drugs === Drugs can have various types of impact on the male body, side effects of medications may affect male fertility, spermatogenesis, and sexual function. Drugs can affect sperm parameters by inhibiting normal exocrine functions of the testes which can lead to a decrease in production of sperm, or by creating hormone imbalances. For an example, anti-androgenic drugs like spironolactone, cimetidine, and ketoconazole can disrupt androgens in the glands and seminal tract to cause a decrease in production of semen volume. Furthermore, common drugs (e.g. tamsulosin) used to treat hypertension and benign prostatic hyperplasia (increased size of prostate) are attracted to dopamine and serotonin receptors in the brain to cause a decrease in sperm volume through a mechanism that remains unknown. Certain medications in the following classes of drugs may affect spermatogenesis or sperm parameters*:
Sources: en.wikipedia.org
== History == Flavoproteins were first discovered in 1879 by separating components of cow's milk. They were initially called lactochrome due to their milky origin and yellow pigment. It took 50 years for the scientific community to make any substantial progress in identifying the molecules responsible for the yellow pigment. The 1930s launched the field of coenzyme research with the publication of many flavin and nicotinamide derivative structures and their obligate roles in redox catalysis. German scientists Otto Warburg and Walter Christian discovered a yeast derived yellow protein required for cellular respiration in 1932. Their colleague Hugo Theorell separated this yellow enzyme into apoenzyme and yellow pigment, and showed that neither the enzyme nor the pigment was capable of oxidizing NADH on their own, but mixing them together would restore activity. Theorell confirmed the pigment to be riboflavin's phosphate ester, flavin mononucleotide (FMN) in 1937, which was the first direct evidence for enzyme cofactors. Warburg and Christian then found FAD to be a cofactor of D-amino acid oxidase through similar experiments in 1938. Warburg's work with linking nicotinamide to hydride transfers and the discovery of flavins paved the way for many scientists in the 40s and 50s to discover copious amounts of redox biochemistry and link them together in pathways such as the citric acid cycle and ATP synthesis.
=== Detection in body fluids === Amphetamine is frequently measured in urine or blood as part of a drug test for sports, employment, poisoning diagnostics, and forensics. Techniques such as immunoassay, which is the most common form of amphetamine test, may cross-react with a number of sympathomimetic drugs. Chromatographic methods specific for amphetamine are employed to prevent false positive results. Chiral separation techniques may be employed to help distinguish the source of the drug, whether prescription amphetamine, prescription amphetamine prodrugs, (e.g., selegiline), over-the-counter drug products that contain levomethamphetamine, or illicitly obtained substituted amphetamines. Several prescription drugs produce amphetamine as a metabolite, including benzphetamine, clobenzorex, famprofazone, fenproporex, lisdexamfetamine, mesocarb, methamphetamine, prenylamine, and selegiline, among others. These compounds may produce positive results for amphetamine on drug tests. Amphetamine is generally only detectable by a standard drug test for approximately 24 hours, although a high dose may be detectable for 2–4 days. For the assays, a study noted that an enzyme multiplied immunoassay technique (EMIT) assay for amphetamine and methamphetamine may produce more false positives than liquid chromatography–tandem mass spectrometry. Gas chromatography–mass spectrometry (GC–MS) of amphetamine and methamphetamine with the derivatizing agent (S)-(−)-trifluoroacetylprolyl chloride allows for the detection of methamphetamine in urine.
In the physical sciences, the spectrum of a physical quantity (such as energy) may be called continuous if it is non-zero over the whole spectrum domain (such as frequency or wavelength) or discrete if it attains non-zero values only in a discrete set over the independent variable, with band gaps between pairs of spectral bands or spectral lines. The classical example of a continuous spectrum, from which the name is derived, is the part of the spectrum of the light emitted by excited atoms of hydrogen that is due to free electrons becoming bound to a hydrogen ion and emitting photons, which are smoothly spread over a wide range of wavelengths, in contrast to the discrete lines due to electrons falling from some bound quantum state to a state of lower energy. As in that classical example, the term is most often used when the range of values of a physical quantity may have both a continuous and a discrete part, whether at the same time or in different situations. In quantum systems, continuous spectra (as in bremsstrahlung and thermal radiation) are usually associated with free particles, such as atoms in a gas, electrons in an electron beam, or conduction band electrons in a metal. In particular, the position and momentum of a free particle has a continuous spectrum, but when the particle is confined to a limited space its spectrum becomes discrete. Often a continuous spectrum may be just a convenient model for a discrete spectrum whose values are too close to be distinguished, as in the phonons in a crystal.
Sources: en.wikipedia.org
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.
Oxidation of the methionine residue to the sulfoxide is a frequently reported change, and it usually appears as an earlier-eluting peak in reversed-phase chromatography. Backbone hydrolysis products can also accumulate in aqueous solution.
Liquid chromatography coupled with mass spectrometry is the usual approach, because the observed molecular ion can be compared with a calculated mass of about 813.9 Da. Retention time alone does not establish identity.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.